Penny stocks can be an enticing category for investors who are just starting out, as they often come with low share prices and the potential for significant gains. However, it's important to remember that investing in penny stocks can be risky, as they are often associated with smaller, less-established companies and can be more volatile. Here are four (4) penny stocks that you may consider adding to your watchlist, but please conduct thorough research and consider your risk tolerance before investing in any of them: 

Futuris Company (OTC: FTRS) is involved in Human Capital Management (HCM) and offers a range of services, including executive search, consulting, staffing services, managed services, and tech services in various fields, such as medical, IT, legal, and recruitment process outsourcing (RPO). Here are some key points based on the information you've provided: 

Futuris recently announced the acquisition of the healthcare staffing business Recruiter.com, among other acquisitions. This acquisition, among others, is expected to generate additional revenues for the healthcare staffing division of the company. It shows that the company is actively pursuing growth through strategic acquisitions.

On October 4, 2023, made a leadership change, appointing a new Chief Executive Officer, Larry Parrotte, who has a background in both staffing and technology sectors. Robert Day, the former CEO, transitioned to the role of Chief Financial Officer. Leadership changes can significantly impact a company's direction and strategy. 

Furthmore, Futuris reported a net profit of $2,980,317 in the fiscal year ending on July 31, 2023, which represents a significant improvement compared to the previous fiscal year when the company recorded a loss of $937,432. A return to profitability indicates positive momentum in the company's financial performance. 

Elite Pharmaceuticals Inc. (OTC: ELTP) is a specialty pharmaceutical company with a focus on niche generic products, including limited-release and immediate-release solid oral dose products. They market their products under the label Elite Laboratories and through licenses granted to third-party distribution and pharmaceutical marketing entities. 

On September 25, 2023, the company announced that it had submitted an abbreviated new drug application (ANDA) on August 17, and the United States Food and Drug Administration (FDA) accepted it for review on September 19. The ANDA was filed for an undisclosed product falling into the category of opiate analgesics. Furthermore, the company mentioned that the twelve-month sales for this product, ending on June 30, 2023, amounted to $720 million for both the branded and generic versions, as per IQVIA reports. 

This filing and acceptance by the FDA for review is a significant step for Elite Pharmaceuticals Inc. It indicates that the company is seeking approval to manufacture and market a generic version of a well-established opiate analgesic product, which could be a lucrative opportunity in the pharmaceutical market. If the application is approved, it would allow Elite Pharmaceuticals Inc. to compete in this market and offer a more affordable alternative to the brand-name version of the product. 

Enzolytics Inc. (OTC: ENZC) recently completed a business combination agreement with Sagaliam Acquisition Corp. (NASDAQ: SAGA) This development appears to be a significant move for the company. The agreement for the sale of its two operating subsidiaries, Virogenetics Inc. and Biogenysis Inc., to Sagaliam Acquisition Corp. The transaction is valued at $450,000,000 and is expected to result in the combined entity being listed on the NASDAQ exchange. The process to de-SPAC (Special Purpose Acquisition Company) has already commenced, and the project is moving forward to closure. 

This business combination has the potential to open various opportunities for both Enzolytics Inc. and the entities it is selling. It can lead to advancements in their respective technologies and potentially expedite the development process. Additionally, the consolidation of resources and expertise from both entities may enable faster progress in the final stages of developing therapeutic products. 

Overall, this strategic move appears to be a positive step for Enzolytics Inc., and it will be interesting to see how the combined entity on the NASDAQ exchange progresses with its therapeutic development initiatives. 

Zomedica Corp. (NYSE American: ZOM) is a veterinary diagnostic and pharmaceutical company that focuses on providing products and solutions for the pet care industry. The company's primary goal is to improve the diagnostic capabilities and overall healthcare of animals, particularly pets. Here's a brief overview of a recent development for Zomedica. 

Zomedica recently announced the acquisition of Qorvo Biotechnologies LLC (QBT), a company known for its OmniaTM and TRUFORMA® point-of-care diagnostic platforms. This acquisition appears to be a strategic move to enhance Zomedica's capabilities in veterinary diagnostics.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com